The closing price of Sanofi (NASDAQ: SNY) was $47.86 for the day, up 1.76% from the previous closing price of $47.03. In other words, the price has increased by $+0.83 from its previous closing price. On the day, 2219765 shares were traded. SNY stock price reached its highest trading level at $47.90 during the session, while it also had its lowest trading level at $47.33.

**From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio**

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

** Get our free report, "Top 5 AI Stocks to Buy for 2023". **

Sponsored

### Ratios:

Our analysis of SNY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.23.

### Upgrades & Downgrades

### Valuation Measures:

As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.59, and their Forward P/E ratio for the next fiscal year is 9.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52 while its Price-to-Book (P/B) ratio in mrq is 1.52.

### Stock Price History:

Over the past 52 weeks, SNY has reached a high of $57.79, while it has fallen to a 52-week low of $36.91. The 50-Day Moving Average of the stock is 48.01, while the 200-Day Moving Average is calculated to be 46.07.

### Shares Statistics:

SNY traded an average of 1.95M shares per day over the past three months and 1.37M shares per day over the past ten days. A total of 2.51B shares are outstanding, with a floating share count of 2.24B. Insiders hold about 16.40% of the company’s shares, while institutions hold 10.30% stake in the company. Shares short for SNY as of Jan 12, 2023 were 2.96M with a Short Ratio of 2.74M, compared to 2.84M on Dec 14, 2022.

### Dividends & Splits

With its trailing 12-month dividend rate of 3.20, SNY has a forward annual dividend rate of 1.90. Against a Trailing Annual Dividend Yield of 6.80%, it implies a Forward Annual Dividend Yield of 3.72%. The stock’s 5-year Average Dividend Yield is 3.86.

### Earnings Estimates

The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was $1.09. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $4.75 and $4.31 for the fiscal current year, implying an average EPS of $4.52. EPS for the following year is $4.98, with 2 analysts recommending between $5.01 and $4.96.

### Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $11.92B to a low estimate of $10.83B. As of the current estimate, Sanofi’s year-ago sales were $10.85B, an estimated increase of 4.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $11.17B, an increase of 3.70% less than the figure of $4.40% in the same quarter last year. There is a high estimate of $11.33B for the next quarter, whereas the lowest estimate is $10.91B.

A total of 4 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $50.05B, while the lowest revenue estimate was $46.94B, resulting in an average revenue estimate of $48.57B. In the same quarter a year ago, actual revenue was $45.17B, up 7.50% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $50.73B in the next fiscal year. The high estimate is $51.76B and the low estimate is $49.77B. The average revenue growth estimate for next year is up 4.40% from the average revenue estimate for this year.